Schroder Investment Management Group’s Zenas BioPharma ZBIO Stock Holding History

Schroder Investment Management Group’s Portfolio ZBIO Stock Details ZBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-33,697	Closed	-$614K	–	1261
2026 Q1	$614K	Sell	33,697 -16,939	-33%	-$380K	﹤0.01%	1073
2025 Q4	$1.85M	Sell	50,636 -61,976	-55%	-$2.04M	﹤0.01%	901
2025 Q3	$2.32M	Sell	112,612 -42,304	-27%	-$689K	﹤0.01%	904
2025 Q2	$1.48M	Sell	154,916 -9,119	-6%	-$88.8K	﹤0.01%	950
2025 Q1	$1.34M	Sell	164,035 -7,905	-5%	-$61.9K	﹤0.01%	954
2024 Q4	$1.55M	Buy	+171,940	New	+$2.68M	﹤0.01%	955

Other funds holding ZBIO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

RPSM

Royalty Pharma Sub-Manager New York $242M AUM

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Schroder Investment Management Group's ZBIO Position: Q2 2026 in Review

Schroder Investment Management Group sold out of Zenas BioPharma (ZBIO) in Q2 2026, closing a stake of 33,697 shares — an estimated $614K sold.

Schroder Investment Management Group first reported a position in ZBIO in Q4 2024 and held it in 6 quarters. The position peaked at $2.32M in Q3 2025. 144 funds tracked by Wall St. Rank hold ZBIO as of Q2 2026.

Schroder Investment Management Group reported no remaining Zenas BioPharma position as of Q2 2026 after selling out during the quarter.
Schroder Investment Management Group sold 33,697 Zenas BioPharma shares in Q2 2026, an estimated $614K.
Schroder Investment Management Group first reported a position in Zenas BioPharma in Q4 2024 and held it in 6 quarters.
Schroder Investment Management Group's Zenas BioPharma position peaked at $2.32M in Q3 2025.
144 funds tracked by Wall St. Rank held Zenas BioPharma as of Q2 2026.

Based on Schroder Investment Management Group's 13F filing for Q2 2026, filed 13 Aug 2026.